+ Watch IMUC
on My Watchlist
It is going to hit 6 dollars by the end of 2014. Biotechnology is on the rise.
ImmunoCellular is yet another dubious outfit that refuses to die after a crushing failure in a clinical trial. The share price bottomed out at 0.72 subsequent to negative results of the phase II trial of ICT-107 in GBM. No statistically significant effect was seen on overall survival, although the secondary endpoint of progression-free survival was positive. The latter doesn't really mean much - people want to live longer. Nevertheless, ImmunoCellular got in touch with their inner sliminess to run a headline that only mentioned the PFS benefit, and only described the failure to meet the primary endpoint in smaller text underneath. The failure was particularly devastating for ICT-107 optimists given the frequent touting of multiple long-term GBM survivors from a small phase I trial of ICT-107 that was conducted at a single facility by a single PI. To ICT-107 skeptics, this was further evidence of the lack of prognostic value of small open label single-arm trials where patient populations can be cherry picked to look good against historical survival data.ImmunoCellular seems to be well on its way to doubling from the lows on the back of chest-beating from management and Seeking Alpha touts. ImmunoCellular will continue to follow the patients from the trial post-blinding and will attempt to glean some positive OS data. The company does seem bent to gathering together enough scraps from the failed phase II to put together a phase III trial. Remember that many consider initiation of a phase III to be sufficient validation of phase II, since there's no hard catalyst of drug approval or rejection involved. The flip side of that coin is that phase III trials are expensive, ICT-107 is not partnered and is unlikely to be partnered, and ImmunoCellular only has 29M in the bank. Expect a significant dilutive financing once this round of puffery levels off.
according to the company, we can expect results from the ict-107 phase II trail.
several good products progressing in the pipeline.
Strong pipeline. low requirement for approval. Just needs to "same or better" then current treatments for GBMF (Brain cancer). and current treatment is frankly poor. Chance of no approval is almost zero.
Research in pipeline
It was picked by www.hechtsoft.de Trade Alerts.
Has a cancer vaccine that appears very promising.
porto. likededded it.
Definitely speculative, but I figure the technology is interesting and some bright phase one clinical trial results are enough for me to take the risk
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions